Dr. Galit Kleiner, a neurologist at Baycrest Centre for Geriatric Health in Toronto, has dedicated nearly two decades to studying paratonia, a movement disorder that causes severe muscle stiffness and pain in dementia patients. This condition, often mistaken for aggression, affects approximately 25% of Canadians over 85. Kleiner's groundbreaking research focuses on an experimental treatment using botulinum toxin (BoNT-A), which has shown promising results in alleviating symptoms. Patients treated with BoNT-A have reported reduced pain and improved mobility, allowing caregivers to provide better care. One notable case is Giovanni Greco, whose family experienced a significant improvement in his quality of life after receiving the injections. Despite the success of this treatment, funding for larger trials remains elusive, and the injections are not covered by provincial health plans, costing around $12,000 annually. Kleiner emphasizes the urgent need to address paratonia as Canada's population ages, with dementia cases projected to reach one million by 2030. Her work aims to transform paratonia from a poorly understood complication into a manageable condition, ultimately enhancing the lives of both patients and caregivers.